AIM AIM ImmunoTech Inc
Company Analysis
Latest News
🟢 AIM ImmunoTech is trading 5.7% up today with broader biotechnology momentum
AIM ImmunoTech is trading 5.7% up at $0.27, with broader biotechnology momentum and improving risk appetite appearing to support the move. - The stock...
🔴 AIM ImmunoTech is trading 5.1% down in pre-market — reason for decline remains unconfirmed
AIM ImmunoTech is trading 5.1% down now at $0.24 in pre-market, with the reason for the decline unconfirmed. - No new company-specific announcement was...
🟢 AIM ImmunoTech is trading 6.21% up today amid biotech momentum after positive Moderna cancer-vaccine news
AIM ImmunoTech is trading 6.21% up at $0.25, apparently amid residual biotech momentum following positive Moderna cancer-vaccine news. - No newly identified...
🟢 AIM ImmunoTech is trading 7.83% up in after-hours trading on biotech-sector strength after positive Moderna cancer-vaccine results
AIM ImmunoTech is trading 7.83% up at $0.26 in after-hours trading after the broader biotech sector rallied on positive Moderna personalized cancer-vaccine...
🟢 AIM ImmunoTech rises 5.2% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 AIM ImmunoTech is trading 11.69% up today with no clear company-specific catalyst
AIM ImmunoTech is trading 11.69% up at $0.25, with no clear company-specific catalyst identified for August 17, 2026. - Recent second-quarter results, the...
🟢 AIM ImmunoTech is trading 6.3% up today — no clear company-specific catalyst identified
AIM ImmunoTech is trading at $0.23 (+6.28%) with no clear company-specific catalyst identified for the August 17, 2026 move. - Recent second-quarter results...
🟢 AIM ImmunoTech is trading 11.6% up in pre-market with no clear company-specific catalyst identified
AIM ImmunoTech is trading 11.6% up in pre-market at $0.25 after closing at $0.22 on August 14, 2026, with no clear company-specific catalyst identified. -...
🟢 AIM ImmunoTech is trading 7.32% up in pre-market with no clear catalyst identified
AIM ImmunoTech is trading 7.32% up at $0.24, with no clear company-specific catalyst identified for the August 17 pre-market move. - The company closed August...
🟢 AIM ImmunoTech is trading 5.7% up in after-hours trading with no clear company-specific catalyst identified
AIM ImmunoTech is trading 5.69% up now at $0.23 after closing August 14, 2026 at $0.22, with no clear company-specific catalyst identified for the after-hours...
🔴 AIM ImmunoTech is trading 15% down today with no clear catalyst identified
AIM ImmunoTech is trading 15% down at $0.22 after no clear company-specific catalyst was identified for August 14, 2026. - Recent coverage focused on August...
🔴 AIM ImmunoTech is trading 5.5% down today with no clear company-specific catalyst
AIM ImmunoTech is trading 5.5% down at $0.24, with no clear company-specific announcement dated August 14, 2026 explaining the decline. - Recent coverage...
AIM ImmunoTech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 13, 2026
AIM ImmunoTech is expected to report a Q2 2026 loss of $0.17 per share on minimal revenue of approximately $0.03 million, with its $0.28 stock price currently...
🔴 AIM ImmunoTech is trading 5.36% down today after $3.8 million Q2 loss misses consensus
AIM ImmunoTech is trading 5.36% down now at $0.25 after its August 10, 2026, second-quarter results showed a $3.8 million net loss and EPS of $(0.43), missing...
AIM CEO Publishes Article Highlighting Ampligen's Potential as Biodefense Therapeutic
AIM ImmunoTech disclosed that its CEO, Thomas K. Equels, published an article in the online media outlet Breaking Defense. The article advocates for the...
🔴 AIM ImmunoTech is trading 5% down today after a $3.8 million Q2 net loss
AIM ImmunoTech is trading at $0.27, down -5.05%, after second-quarter results showed a $3.8 million net loss. - The company reported $9.9 million in cash and...
AIM ImmunoTech Posts Wider Losses on Thin Revenue — Can $9.9 Million in Cash Buy Enough Time?
Shares of AIM ImmunoTech slid 7.5% to $0.26 after the micro-cap biotech reported second-quarter results that showed a familiar pattern: negligible revenue,...
🔴 AIM ImmunoTech is trading 7.5% down in pre-market after net loss widened to $3.79 million
AIM ImmunoTech is trading 7.53% down in pre-market at $0.26 after reporting second-quarter results on August 7, 2026, which showed a net loss of $3.79...
Aim ImmunoTech second quarter 2026 cash reaches $9.9M as pancreatic cancer trial enrollment concludes
Aim ImmunoTech reported a second quarter 2026 net loss of $3.8 million, or $0.43 per share, while significantly improving its liquidity position. The company...
AIM ImmunoTech Returns to Positive Equity, But Flags 'Going Concern' Risk
AIM ImmunoTech reported positive stockholders' equity of $7.7 million as of June 30. This was included in its second-quarter 2026 report. The company...